Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024 - Celldex Therapeutics ( NASDAQ:CLDX )

3 weeks ago

HAMPTON, N.J., Oct. 25, 2024 ( GLOBE NEWSWIRE ) -- Celldex Therapeutics, Inc.

Ticker	Sentiment	Impact
CLDX	Neutral	17 %